New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
09:47 EDTLCILannett could see decreased digoxin sales, says Craig-Hallum
Last week an article in the Journal of American College of Cardiology, or JACC, highlighted concerns regarding increased mortality for Digoxin users. Craig-Hallum said Digoxin is one of Lannett's top drugs and believes the study combined with the push-back on last year's price increase could lead to a decrease in Digoxin sales. Shares are Buy rated but the analyst is growing more cautions near-term.
News For LCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2015
08:44 EDTLCILannett steady execution offers compelling upside, says Susquehanna
Susquehanna noted Lannett delivered solid Q2 results and outlook and believes its stock price is undervaluing the upside potential from new products and business development. The firm also sees the potential for multiple expansion if volume trends remain steady. Susquehanna reiterated its Positive rating but lowered its price target to $70 from $75 on Lannett shares.
August 25, 2015
16:08 EDTLCILannett sees FY16 CapEx $60M-$70M
Which includes $30M to continue the partial fit-out of company-owned buildings. Sees FY16 gross margin as a percentage of net sales of approximately 71%-73%; R&D expense in the range of $33M-$35M; SG&A expense ranging from $57M-$59M, which includes approximately $5M in acquisition-related expenses; The full year effective tax rate to be in the range of 34%-35%.
16:06 EDTLCILannett sees FY16 revenue $425M-$435M, consensus $433.55M
16:05 EDTLCILannett reports Q4 EPS 91c, consensus 86c
Reports Q4 revenue $99.3M, consensus $97.62M.
August 18, 2015
07:59 EDTLCILannett subsidiary receives approval for Aripiprazole Oral Solution
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use